# The HIV Prevention Pipeline

#### In development: Preclinical and clinical



Long-acting implants



Multipurpose vaginal ring

Preventive vaccines



**Patches** 

Douche



Long-acting

vaginal ring

Vaginal Film



Vaginal Gel



Iniectable



Inserts

**Broadly** neutralizing antibodies

## In development: Efficacy trials under way



Monthly oral PrEP MK-8527



Daily oral PrEP



Combo oral PrEP/OC

Possible dual pill to market by 2026 <sup>2</sup>

### **Newly Approved and** Recommended



Dapivirine vaginal ring



Injectable cabotegravir



Iniectable lenacapavir

And in implementation science projects:

www.prepwatch.org/resources/ implementation-study-tracker/

## **Currently available**



**HIV** treatment for people living with HIV/U=U



Male & female condoms



Voluntary medical male circumcision



Syringe exchange programs



Daily oral PrEP





Event-driven for some populations

<sup>&</sup>lt;sup>1</sup> In Oct 2019, US FDA approved F/TAF for adults and adolescents who have no HIV risk from receptive vaginal sex; still in development for cisgender women.

<sup>&</sup>lt;sup>2</sup> Efficacy trials not required; bioequivalency of the two approved products when dosed together may be all that is required.